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Background: Telomeres are protective caps consisted of specific tandem repeats (5′-TTAGGG-3′). Shortening of
telomeres at each cell division is known as “mitotic clock” of the cells, which renders telomeres as important
regulators of lifespan. TRF2 is one of the critical members of shelterin complex, which is a protein complex
responsible from the preservation of cap structure, and loss or mutation of TRF2 results in DNA damage, senescence or
apoptosis. Since cancer is frequently associated with aberrant cell cycle progression, defective DNA repair or apoptosis
pathways, TRF2 could be one likely candidate for cancer therapy.
Here we investigated the prognostic role of TRF2 levels in cervical cancer patients. Fold-induction rates were evaluated
with respect to median values after real-time PCR analysis. Overall survival, distant disease-free and local recurrence-free
survival rates were calculated using Kaplan-Meier long rank test.
Results: Both five year overall- and disease-free survival rates were longer in patients with higher TRF2 expression
compared to lower expression, but results were not statistically significant (69.2% vs 28.9%, respectively). Mean local
recurrence-free survivals (LRF) were very close ( 58.6, CI: 44.3-72.9 vs 54.5, CI: 32.1-76.9 months) for high and low
expressions, respectively. Cumulative proportion of LRF at the end of five year period was 76.9% for high and
57.1% for low TRF2 expression (P = 0.75). Statistically significant difference was found between survival ratios and
Bcl-xL and p53 gene expressions, but not with TRF2. A respectable correlation between TRF2 expression and
apoptosis along with distant metastasis was noted (P = 0.045 and 0.036, respectively). Additionally, high TRF2
expression levels had a positive impact in five year survival rate of stage IIIB-IVA patients (P = 0.04).
Conclusions: Our results support the role of TRF2 in apoptosis and imply a positive relation with distant metastases
and survival in advanced stage patients. The remarkable difference in survival periods of patients with different TRF2
expressions suggest that TRF2 may be a candidate factor to estimate survival for cervical cancer, a preliminary
observation which should further be verified with a larger cohort.
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Telomeres are protective caps consisted of specific tan-
dem repeats (5′-TTAGGG-3′). Shortening of telomeres
at each cell division is known as “mitotic clock” of the
cells, which renders telomeres as important regulators of
lifespan. The cap structure of telomeres is preserved by
shelterin complex consisted of six proteins, telomere
repeat-binding factors 1 and 2 (TRF1, TRF2), protection
of telomeres protein 1 (POT1), heterodimeric partner of
POT1 known as TPP1, TRF1-interacting nuclear factor* Correspondence: drsevgi@hekim.net
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unless otherwise stated.TIN2 and RAP1 [1,2]. This structural organization serve
to protect ends of chromosomes from end fusions or
DNA repair proteins and participates to the genomic
stability. TRF2 is one of the critical members of shelterin
complex and loss or mutation of TRF2 results in DNA
damage, senescence or apoptosis [3,4]. Since cancer is
frequently associated with aberrant cell cycle progres-
sion, defective DNA repair or apoptotic pathways, TRF2
could be one likely candidate for cancer therapy.
Cervical cancer is one of the most common malignant
gynecological disorders, especially in less-developed
countries. Even though this cancer type is mostly based
on human papilloma virus infection, 5-year overall sur-
vival rates are still around 52% after application ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Kaplan-Meier survival analysis for overall (OS) with









IIB (7) 85.3 73.9-96.8 85.7 0.02*
IIB-IVA(13) 53.7 32.7-70.1 38.5
Age
>56 years 71.3 56.3-86.4 60 0.28
<56 years 57.8 37.1-78.4 50
Apoptosis (n) 0.18
High (9) 70.7 52.7-88.6 63.6
Low (11) 57.4 39.1-75.7 44.4
Grade (n) 0.06




*Correlation is significant at the 0.05 level (2-tailed).
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cervical cancers, integration of virus DNA into host’s
DNA results in the overexpression of especially two viral
oncogenes, E6 and E7, which deregulates both cell cycle
and apoptosis in the cell. Activation of telomerase re-
verse transcriptase (TERT) by E6 is one of the crucial
steps causing immortalization [6].
In addition to telomerase activation, infection by high-
risk HPV types has been found to be associated with gen-
omic instability [7]. Genomic instability is a well-known
factor driving the cells to a malignant phenotype. There
are wide varieties of factors contributing to genomic in-
stability and giving rise to high heterogeneity among the
tumor cells. Since TRF2 is an important element of telo-
mere homeostasis and loss of TRF2 yields end-to-end fu-
sions, telomere shortening, activation of DNA damage
pathways, TRF2 regulation could be a contributing factor
in cancer progression [4]. In accordance with this hypoth-
esis, TRF2 overexpression is detected in various tumor
types like gastric carcinoma, hepato-carcinogenesis or
colorectal carcinoma [8-10]. Regulation of TRF2 expres-
sion was found to be correlated with tumor grade in lung
cancer progression [11].
As human telomerase and the cap structure at telomere
regions are important contributors of instability and cancer
progression, we wanted to know potential role of TRF2
protein, an important protector of cap structure, on the
prognosis of advanced stage cervical cancer patients. Gene
expression of TRF2 was quantified by real-time PCR.
Values were normalized relative to β-actin levels and com-
pared to previously determined levels of apoptotic gene
B-cell lymphoma-extra-large (Bcl-xL) and tumor suppres-
sor p53. Bcl-xL is an anti-apoptotic protein and relative
expression of anti- and pro-apoptotic proteins are the
determinants of cells’ faith on survival. p53, on the other
hand, is a well-known tumor suppressor, mutation of which
was shown to lead uncontrolled cell proliferation.
In this study, Association between TRF2 expressions
and survival rates of advanced stage cervical cancer pa-
tients has been investigated and correlations of TRF2 ex-
pression with above mentioned elements of cell survival
and apoptosis were determined in this perspective.
Results
TRF2 expression was determined in cervical cancer pa-
tients admitted to the Dr. Lutfi Kirdar Kartal Training and
Research Hospital Radiation Oncology Department. The
mean follow up period was 63.2 months (standard error of
the mean (S.E.M) was 6.6). Histopathological evaluations
of patients revealed that 40% has invasive and 60% has
large cell squamous cell type. Expression levels were de-
termined using real-time PCR analysis and values were
normalized against house-keeping gene beta-actin. Fold-
induction ratios were evaluated and assessed as “high” or“low” with respect to the average of the group. The mean
from a small pool of normal cervical tissue was used as
complementary reference. Median age of patients was 56
(range 39–75). Overall survival rates at the end of 5 year
period were analyzed against clinical parameters of the pa-
tients (Table 1). Survival times were straightly correlated
with the stage and grade of the disease as expected. In
addition, grades were also strongly correlated with distant
metastases (P = 0.001), while neither grade nor histopatho-
logical types found to be correlated with gene expressions.
There was no apparent relation between survival and
apoptosis.
Immunohistochemical evaluation of apoptotic cells were
determined by TUNEL staining as described in methods.
Sections from the paraffin block firstly deparaffinized and
proceeded according to kit’s instructions. Apoptotic nuclei
were visualized using the DAB substrate, which resulted
in brown precipitate.
Mean survival was found as 65 months (S.E.M. 6.7)
with 95% confidence interval (CI), 51.8-78.4. Mean over-
all survival time in patients with higher TRF2 expression
than average was longer compared to lower expression
levels, as 73.0 months (S.E.M. 7.5) vs 49.9 months (S.E.
M. 11.2) with 95% CI, 58.1-87.8 and 27.9-71.9 respect-
ively. Again, 5-year overall- and disease-free survival rates
were longer in patients with higher TRF2 expression com-
pared to lower expression (69.2% vs 28.6% for overall and
the same for disease-free survivals, respectively), but re-
sults were not statistically significant (Table 2). The
Kaplan-Meier survival curve of the log-rank analysis expli-
citly showed that low OS (overall survival) expression
levels might well be related to relative low level TRF2 ex-
pression (Figure 1). Local control means were very close
Table 2 Kaplan-Meier survival analysis for overall (OS), disease-free (DFS) and local-recurrence free (LRF) survival
relative to gene expressions (n): number of patients
OS means (months) 95% CI (months) OS (5 years)% p-value
TRF2 (n)
High expression (13) 73.0 58.1 – 87.8 69.2 0.154
Low expression (7) 49.9 27.9 – 71.9 28.6
Bcl-xL (n)
High expression (11) 46.5 30.4-62.7 27.3 0.002*
Low expression (9) 86.8 77.7-95.9 88.9
p53 (n)
High expression (9) 48.6 29.3-67.9 33.3 0.02*
Low expression (11) 78.1 64.2-91.9 72.7
DFS means (months) 95% CI (months) DFS (5 years)% p-value
TRF2 (n)
High expression (13) 70.3 53.3 – 87.3 69.2 0.124
Low expression (7) 43.9 21.1 – 66.8 28.6
Bcl-xL (n)
High expression (11) 41.1 23.9-58.4 27.3 0.003*
Low expression (9) 84.8 72.0-97.5 88.9
p53 (n)
High expression (9) 45.8 25.7-66 33.3 0.04*
Low expression (11) 73.4 55.4-91.2 72.7
Local control means (months) 95% CI (months) LRF (5 years)% p-value
TRF2 (n)
High expression (13) 58.7 44.4-72.9 76.9 0.750
Low expression (7) 54.5 32.2-76.9 57.1
Bcl-xL (n)
High expression (11) 45.4 26.4-64.3 45.5 0.01*
Low expression (9) 71.6 66.0-77.0 88.9
p53 (n)
High expression (9) 49.5 28.4-70.7 55.6 0.10
Low expression (11) 43.4 30.7-76 72.7
*Correlation is significant at the 0.05 level (2-tailed).
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54.5 months [95% CI, 32.1- 76.9] for high and low expres-
sions, respectively. Cumulative proportion of local recu-
rrence free survival (LRF) surviving at the end of 5 year
period was 76.9% for high and 57.1% for low TRF2
expression.
Anti-apoptotic protein Bcl-xL and tumor suppressor
protein p53, on the other hand, were markedly related to
the survival ratios. 88.9% of patients with lower Bcl-xL ex-
pression had better survival time at the end of 5-year
period (P = 0.002). The corresponding value was 72.7% for
p53 expression (P = 0.02), in concert with its role as tumor
suppressor (Table 2).
Spearman correlation analyses involving genes of inter-
est, namely Bcl-xL, p53 and TRF2, together with apoptosisand distant metastasis, were introduced in Table 3. TRF2
was found to be related with number of apoptotic cells de-
termined by TUNEL method (P = 0.045). This value was
0.069 for Bcl-xL and 0.369 for p53 protein. Local recur-
rence and differentiation were not correlated with any
gene expression involved in this study (not shown)
whereas presence of distant metastasis was negatively cor-
related with TRF2 (P = 0.036) (Table 3). High expression
of TRF2 also resulted in longer survival in high grade pa-
tients when compared to low TRF2 expression group with
high grade (mean survival was 58 months, S.E.M. 11.3, vs
45 months, S.E.M. 11.8, respectively), but results were not
statistically significant (P = 0.14). The comparison of five
year survival rates with the expression levels of Bcl-xL,
p53, together with TRF2, on the other hand, were in close
Figure 1 Kaplan-Meier survival curves with univariate log-rank
comparisons for 8 year follow up period for TRF2 expression.
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in Table 4.
As a protector of chromosome ends, high TRF2 levels
had a positive impact on survival. There was no correlation
between TRF2 and p53 expressions though it is known
that shortage of TRF2 induce Ataxia Telangiectasia Mu-
tated kinase (ATM) and p53 mediated apoptosis by activat-
ing DNA damage signal mechanism [12].
Discussion
We studied the expression of TRF2, a telomere-associated
protein and Bcl-XL and p53 genes in tumor tissues of cer-
vix cancer patients and observed considerable differenceTable 3 Spearman correlations for TRF2, Bcl-xL, and p53, tog
and apoptosis and differentiation (Diff)
TRF2 Bcl-xL Apoptosis
TRF2 1,000 −0,032 0,453 −
P-value - 0,895 0,045* 0
Bcl-xL −0,032 1,000 0,414 0
P-value 0,895 - 0,069 0
Apoptosis 0,453 0,414 1,000 0
P-value 0,045* 0,069 - 0
p53 −0,082 0,212 0,192 1
P-value 0,731 0,369 0,418
DM −0.474 0.328 0.082 0
P-value 0.036* 0.158 0.731 0
LR −0,303 0,522 0,189 0
P-value 0,195 0,018* 0,424 0
Stage 0,216 −0,474 −0,267 −
P-value 0,359 0,035* 0,256 0
Diff −0,171 0,082 −0,082 −
P-value 0,471 0,731 0,731 0
*Correlation is significant at the 0.05 level (2-tailed).in patients’ response with respect to relative protein
expressions. Comparisons of mRNA levels and their post-
operative long-term follow-up results were reported in ad-
vanced stage cervix cancer patients. Our results reveal that
69% of patients who have high intrinsic TRF2 expression
had better survival periods (2.4 fold higher than the group
with lower expression). Relative TRF2 levels were similarly
associated with relative numbers of apoptotic cells, with a
significant pair correlation (P = 0.045).
As a multifactorial event, cancer progression utilizes
multiple components, one of them being the chromosomal
instability. Induction of chromosomal instability through
an unknown mechanism may be an important element to
estimate long-term toxic effects of chemo-radiotherapy,
tumor resistance or side-effects of the therapy as part of
the novel personalized approaches in therapeutic applica-
tions. Telomerase enzyme and shelterin complex are pro-
tectors of telomere structure and function, thereby also
protector of genome, preventing activation of DNA repair
mechanisms at chromosome ends, such as end-to-end fu-
sions, non-homologous end joining (NHEJ) etc. [4].
Cervical cancers differ from other types of cancer in
that tumorigenesis is often a result of viral infection. E6
and E7 oncoproteins of human papilloma virus (HPV),
virus responsible from nearly 70% of all cervical cancers,
interferes with the cell-cycle and apoptosis regulatory
pathways, initiating malignant transformation. E6 binds
to the tumor suppressor protein p53 and directs it to
ubiquitin-mediated degradation and E7 acts on retino-
blastoma regulated network. However, integration ofether distant metastasis (DM), local recurrence (LR), stage
p53 DM LR Stage Diff
0,179 −0.471 −0,300 0,216 −0,171
,450 0.036* 0,195 0,359 0,471
,212 0.328 0,522 −0,474 0,082
,369 0.158 0,018* 0,035* 0,731
,192 0.082 0,189 −0,267 −0,082
,418 0.731 0,424 0,256 0,731
,000 0.082 0,436 −0,267 −0,082
- 0.731 0,055 0,256 0,731
.082 1.000 0,471 −0,391 0,667
.731 - 0,036* 0,088 0,001*
,436 0,471 1,000 −0,371 0,235
,055 0,036* - 0,107 0,317
0,267 −0,391 −0,371 1,000 −0,361
,256 0,088 0,107 - 0,118
0,082 0,667 0,235 −0,361 1,000
,731 0,001* 0,317 0,118 -
Table 4 Comparison of clinicopathological parameters against TRF2, Bcl-xL and p53 expressions
TRF2 expression (n) OS (5 year,%) Bcl-xL expression (n) OS (5 year,%) p53 expression (n) OS (5 year,%)
Stage (n) High Low High Low High Low
IIB (7) 5 2 2 5 3 4
n.d. 50 n.d. 80 66.7 n.d.
IIIB-IVA (13) 8 5 9 4 6 7
50 20 11 n.d. 16.7 57.1
P log rank 0.04* 0,006* 0,01*
Histologic grade (n)
High grade (12) 7 5 7 5 5 7
42 20 28** 80 40** 57.1
Low grade (8) 6 2 4 4 4 4
83 50 75 n.d. 75 n.d.
P log rank 0,14 0,01* 0,01*
*Correlation is significant at the 0.05 level (2-tailed); ** 3-year survival; n: number of patients; n.d.: not determined, all censored.
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ation, therefore whether genomic instability is a cause or
a result of infection remains controversial [13].
Characteristics of tumor such as grade, stage, tumor size
or localization are important prognostic factors in cervical
cancer, as in the other types. However, genetic prognostic
factors influencing survival are not yet well established. We
have previously determined the role of several apoptotic
factors in this perspective and found that a relatively new
anti-apoptotic and reactive-oxygen-species (ROS) scaven-
ger protein, sensitive-to-apoptosis (SAG) gene product, has
a positive impact on prognosis of colorectal patients [14].
TRF2 is a small protein that binds to telomeric repeat
units and stabilizes the DNA t-loop structure at telomere
regions. The clinical potential of telomeric proteins in the
treatment of cancer was subject of research by several
studies [15-18]. The altered expression of telomere cap-
ping factors, such as TRF2, could enhance telomeric
damage, cause to an instability at chromosomal ends,
telomerase dependent shortening of telomeres and un-
desirable activation of DNA repair mechanisms. TRF2 is
crucial in cap structure stabilization, it is an active DNA
damage response protein and furthermore it even regu-
lates polymerase activity of DNA polymerase β on telo-
meric and non-telomeric DNA substrates [19-21]. The
potential role of TRF2 expression in solid tumors has been
demonstrated in several studies. Overexpression of TRF2
was reported in variety of carcinomas, such as breast car-
cinomas, gastric carcinomas, colorectal carcinoma cells
[22,23,10]. The transcription levels of TRF2 was found to
be higher in benign samples and decreased with increasing
stage and disease progression in human breast cancer tis-
sue samples [22].
It is known that inhibition of TRF2 expression initiate
apoptosis in many cell types [12]. Inhibition of TRF2 in-
duces immediate alteration in cap structure and activatesATM or p53 dependent response pathways [24] p53, on
the other hand, is a mediator of mitochondrial apoptotic
pathway, mobilizing several downstream targets. There-
fore assessment of differential expressions for TRF2 and
previously determined apoptotic and cell survival related
genes (Bcl-xL, p53) could provide valuable informations
about the relationship between apoptosis, chromosomal
stability and CRT treatments.
Here, we aimed to determine relative expressions of
telomeric factor TRF2 in cervical-cancer tissues and its
possible relation to survival, apoptosis and response to
CRT treatments. TRF2 was found to be correlated weakly
to apoptosis, but not to the survival. Although apoptosis
related to TRF2 levels, expressions of apoptotic proteins
did not show any correlation with TRF2 expressions. This
result is not surprising since TRF2 induced activation of
apoptosis possibly occurs through initiating chromosomal
instability rather than activation of mitochondrial apop-
totic proteins. Statistical evaluations were limited due to
the small population size available. Besides the difficulty
to obtain normal tissue in advanced stage patients and to
separate it from tumor has prevented straight comparison
relative to the same source. Results of our study indicate
that Bcl-xL and p53 are strong candidates to estimate sur-
vival and prognosis as expected. TRF2 has a positive im-
pact on survival and well correlated with apoptosis and
distant metastases. Establishment of TRF2’s effect on sur-
vival through apoptosis reguires further investigation with
larger cohort.
Conclusion
Our results show that TRF2 expression is correlated with
apoptosis, but not with the apoptotic gene expressions.
A clear discrepancy exists between the survival rates of
patients presenting high or low TRF2 expressions, but the
results were not statistically significant. The observed
Ozden et al. Biological Research 2014, 47:61 Page 6 of 7
http://www.biolres.com/content/47/1/61correlation between high TRF2 expression and longer life
spans of advanced stage cervical cancer patients suggests
that TRF2, an important factor in chromatin stability and
survival, might be a candidate factor to estimate survival
in cervical cancers.
Methods
Study population and therapy
Tissues were collected from patients diagnosed with
cervical cancer at Dr. Lutfi Kirdar Kartal Training and
Research Hospital. The patient samples were classified
according to Federation of Gynecology and Obstetrics
(FIGO) system between stages IIB to IVA. Tissue sam-
ples were collected from patients after the receipt of formal
ethical approval from the appropriate ethical committees
related to the institution. All patients provided written
informed consent before undergoing diagnostic cervical
biopsy.
Patients were treated with a combination of external
beam radiation therapy and high-dose-rate (HDR) re-
mote control after-loading intra-cavitary radiation ther-
apy. External pelvic irradiation was administered with
6–15 MV photon X-rays, where intra-cavitary radiation
therapy was administered with HDR - Curietron Cesium-
137 sources. A total dose of 50 Gy was delivered in 25–28
fractions as five fractions per week; afterwards, 20 Gy was
delivered as brachytherapy at point A in three fractions as
one per week. A short 1–2 hour infusion of cisplatin
(40 mg/m2/d, once in a week) was applied as concomi-
tantly during external radiotherapy. Regular follow-up
consisted of physical examinations with 3 months inter-
vals during the first two years, every 6 months interval
thereafter. Patients in whom signs of metastatic disease
were present underwent further investigations. Disease re-
lapse was defined as either local recurrence or the develop-
ment of metastasis and was determined by clinical and
radiographic studies with CT or MRI or by tissue biopsy
invariably. Overall- , disease free and local recurrences free
survival percentages were determined for five years period.
Real-time polymerase chain reaction
Total RNA was extracted from biopsies and processed
as described previously [14]. Briefly, one microgram of
total RNA was reverse transcribed using Transcriptor
High Fidelity cDNA Synthesis kit (Roche Applied Sci-
ence, Manheim, Germany) according to the manufac-
turer’s guidelines. cDNA’s were diluted 10 times and
used as a template in real-time PCR reactions. TRF2
primers used in the analysis were: forward (5′- CGG
GAT CCA TGG CCG ACG TGG AAG-3′) and reverse
(5′- CGA AGC TTT CAT TTG CCG ATT CTT TGG
AC-3′). Other primers for apoptotic protein Bcl-xL and
tumor suppressor p53 were as follows: Bcl-xL forward
(5′-CCA GAA GGG ACT GAA TCG-3′) and reverse(5′-CCT TGT CTA CGC TTT CCA C-3′), p53 for-
ward (5′-AGG CCT AAC TCA AGG AT-3′) and re-
verse (5′-CCC TTT TTG GAC TTC AGG TG-3′).
Apoptosis –TUNEL assay
Apoptotic cells were defined by terminal-deoxynucleoti-
dyltranferase (TdT)-mediated deoxyuracil triphosphate
(dUTP) nick-end labeling (TUNEL) using the ApopTag
Plus Peroxidase in situ apoptosis detection kit (Merck
Millipore, Darmstadt, Germany). The assay was per-
formed in accordance with instructions of manufacturer,
with minor modifications. After the color reaction with
DAB (3,3′diaminobenzidine) apoptotic cells were ob-
served brown, while counter staining was managed using
methyl green to observe living cells. Apoptotic cells were
detected by standard light microscopy, live and death
cells were counted by two independent observersin a
minimum of 5 frames.
Statistical analysis
Survival curves were plotted according to the Kaplan-
Meier method, the log-rank test being used to determine
significant differences with respect to expressions. Cor-
relations were determined by Spearman correlation tests.
Statistical analyses were performed using the SPSS pack-
age (Version 16.0; SPSS Inc., Chicago, IL, USA).
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